Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (3103)	5/29/1999 12:17:00 AM
From: BDR	Respond to of 10280

To the thread- forgive me if this has already been mentioned, but I thought the thread might find it of interest. biz.yahoo.com Sepracor Added To Roster Of Biotech Companies Presenting To Individual Investors In Boston June 7 BOSTON--(BUSINESS WIRE)--May 28, 1999--Sepracor (Nasdaq:SEPR - news) has joined the roster of biotechnology companies presenting to individual investors at the Second Annual Boston Biotechnology Stocks Forum Monday June 7 at the Back Bay Hilton. This Forum runs from 8:30 a.m.-4:30 p.m. Cost is $25 prepaid, $40 at the door. Register at www.informedinvestors.com or call 800-992-4683. The Forum will be audiostreamed live and archived and also audiotaped. The website has details. ''Sepracor is a very interesting story,'' said Tim Quast, President of Informed Investors Forum, sponsor of the event. ''The stock is off 60% in less than three months. It reached $140 on March 8 and is now trading in the 60s. The debate is whether the pummeling is overdone. ''Sepracor's value eroded when the whisper mill apparently guessed -correctly - that Johnson & Johnson (Nyse:JNJ - news) said it would not co-market Sepracor's new version of J&J's Hismanal, an allergy drug. Sepracor's stock suffered because analysts are apparently not convinced Sepracor can market its own drug, norastemizole, alone. Some analysts reduced their estimates of Sepracor's earnings string with the loss of the marketing partnership. ''But other analysts view the situation as an opportunity,'' Quast said. ''They believe J&J decided not to co-market the drug with Sepracor because J&J simply doesn't intend to focus on the respiratory market. Schering Plough's (Nyse:SGP - news) and Pfizer's (Nyse:PFE - news) Zytec are already strong in this market. There is very real potential here though. If Sepracor can successfully market the drug on its own, if it chooses to do so, the company shares revenues with no one, and that positions Sepracor to move into rarified biotech air. And as one analyst pointed out, Sepracor's ability to quickly get improved drugs approved at the FDA is well known.''